Returning for its 7th year, IMPACCT: Real World Evidence provides top innovators and leaders in the real world evidence space with a comprehensive industry forum dedicated to suppo
NICE is to review how it develops guidance on drugs, focusing on issues such as modifiers used in decision making and dealing with uncertainties in evidence.
New payment models, dedicated investment, and better health technology assessment are among a raft of changes needed to bring regenerative medicines to patients in Europe, according to a ne
New rare disease treatments face a complex market access landscape that presents fundamental challenges for pharmaceutical companies seeking to achieve launch excellence.
President Donald Trump is preparing an executive order outlining a “favoured nations clause”, where US prices will reflect those in the country paying the least for their medicines.